Ewing Sarcoma is a rare cancer that occurs in about 2-3 cases per million people. It is aggressive with a variable course where each case requires its own treatment approach. Several types of sarcomas are newly identified that are related to Ewing Sarcoma but are new known to have unique features and may need to be treated differently. The rarity and complexity of Ewing Sarcoma and related diseases make it difficult to conduct high quality research with large patient samples. There is an urgent unmet need for sarcoma specialists to collaborate to create large databases which are critically needed to conduct well-powered research. The Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) is a group of sarcoma care providers across Canada committed to form a multicentre collaborative team to generate and maintain such a database. This study is a part of this pan-Canadian initiative that we would like to contribute Alberta (AB) provincial patient data including both children/adults with Ewing Sarcoma and related disorders. This participation will enable AB patients to have their data included in future research and create opportunities for AB investigators to lead clinical and translational research to improve outcomes for patients with Ewing Sarcoma and related disorders


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Inclusion criteria:

Any patients who were/are diagnosed with Ewing Sarcoma or Ewing-like Sarcoma (also called Undifferentiated Round Cell Sarcoma) will be suitable for this study.

Exclusion criteria:

Patients who did/do not have a diagnosis of Ewing Sarcoma or Ewing-like Sarcoma (Undifferentiated Round Cell Sarcoma) or declined to share their clinical information will not be suitable for this study


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

PI: Xiaolan Feng Co-PI: Bilal Marwa, Michael J Monument, Jan-Willem Henning, Omar Khan, Hatim Karachiwala, Melanie Finkbeiner, Matthew Anaka, Sarah McKillop

Principal investigator:

Xiaolan Feng

Clinical trial: